ArticleFrontiers in endocrinology2025
The gut microbiome: a vital link to hyperuricemia, gout and acute flares?
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Trial
- ABCG2 transporter: Structural and functional associations with gout (Review).International journal of molecular medicine · 2026Review
- Bile Acid Metabolism in Gout Pathogenesis from Gut-Liver-Joint Crosstalk to Therapeutic Opportunities.Metabolites · 2026Review
- Butyrate and Butyrate-Producing Bacteria in Cardiovascular-Kidney-Metabolic Syndrome.Antioxidants (Basel, Switzerland) · 2026Review
- Cold-Adapted Uric Acid-DegradingMolecules (Basel, Switzerland) · 2026Article
- The roles of gut microbiota and their metabolites in uric acid-related metabolic diseases: mechanisms and therapeutic targets.Frontiers in microbiology · 2026Review
- Research progress on the correlation between gut microbiota and the occurrence of hyperuricemia.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To explore the associations between the gut microbiome and asymptomatic hyperuricemia, as well as acute gout flares. Methods: Forty-three Chinese participants were divided into healthy and hyperuricemic groups according to serum uric acid (SUA) levels. The hyperuricemia group were further separated into asymptomatic hyperuricemia (HUA) and gout patients on the basis of their clinical symptoms. In addition, the gout group was further divided into intercritical gout and acute gout groups on the basis of the claim of joint pain and relevant clinical parameters. 16S rRNA sequencing was used to evaluate the microbiome composition of all the groups. Results: A dramatic decreasing trend in microbial richness and diversity was observed in hyperuricemic patients compared with healthy controls. The same decreasing trend in microbial relative abundance was also observed. The butyrate-producing genera Faecalibacterium, Coprococcus and Enterococcus were markedly decreased in hyperuricemic patients. Moreover, opportunistic pathogens, such as the phylum Proteobacteria and genus Fusobacterium, were enriched in the hyperuricemia group. Furthermore, the gut microbiota of gout patients also exhibited significantly reduced microbial diversity compared with asymptomatic hyperuricemic patients, characterized by decreased richness of the genera Dialister, Ruminococcus, and Faecalibacterium. Greater differences in microbial richness and diversity can still be observed when gout flares occur. The abundances of Bacteroides and Lachnospira genera decreased in the acute gout stage. Conclusion: Our study revealed that community richness and diversity change during the process of gout or HUA, especially during acute gout flares. Metagenomic species were significantly altered during different stages of hyperuricemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.